Clinical Trial Update: A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

View source ↗

Summary

This document outlines a real-world, single-arm study protocol evaluating disitamab vedotin in combination with immunotherapy and multimodal radiation therapy f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: West China Hospital | Conditions: HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Status: NOT_YET_RECRUITING